These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3530298)

  • 1. Once a day verapamil in essential hypertension.
    Müller FB; Ha HR; Hotz H; Schmidlin O; Follath F; Bühler FR
    Br J Clin Pharmacol; 1986; 21 Suppl 2(Suppl 2):143S-147S. PubMed ID: 3530298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentration and antihypertensive effect of slow-release verapamil.
    Schütz E; Ha HR; Bühler FR; Follath F
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S346-9. PubMed ID: 6184566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effects of slow-release verapamil in relation to plasma concentration in aged hypertensives. A study with continuous monitoring of arterial pressure and electrocardiogram].
    Canonico V; Bonaduce D; De Caprio L; Nicolino A; Forgione L; Petretta M; Rengo F
    G Ital Cardiol; 1990 Oct; 20(10):924-32. PubMed ID: 2090531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new sustained-release formulation of verapamil in the treatment of hypertension.
    Midtbo KA; Hals O; Lauve O
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):125S-132S. PubMed ID: 3540222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of mild hypertension with low once-daily doses of a sustained-release capsule formulation of verapamil.
    Davis PJ; Fagan TC; Topmiller MJ; Levine JH; Ferdinand KC
    J Clin Pharmacol; 1995 Jan; 35(1):52-8. PubMed ID: 7751413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group.
    Holzgreve H; Distler A; Michaelis J; Philipp T; Wellek S
    BMJ; 1989 Oct; 299(6704):881-6. PubMed ID: 2510877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained release verapamil in hypertension. Results from a noninvasive ambulatory blood pressure monitoring and a clinical study.
    Nissinen A; Koistinen A; Tuomilehto J; Sundberg S; Gordin A
    Eur J Clin Pharmacol; 1986; 31(3):255-9. PubMed ID: 3539623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of mild to moderate hypertension with verapamil slow-release in outpatients. Collaborative Group of the Spanish League for the Fight Against Hypertension.
    Gómez Pajuelo C; Pérez Naranjo J; Ruiz Martínez I
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S50-2. PubMed ID: 2475687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of 'once daily' verapamil for the treatment of hypertension using ambulatory, intra-arterial blood pressure recording.
    Caruana M; Heber M; Brigden G; Raftery EB
    Eur J Clin Pharmacol; 1987; 32(6):549-53. PubMed ID: 3653223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Instant and sustained-release verapamil in the treatment of essential hypertension.
    Midtbø K; Hals O; van der Meer J; Storstein L; Lauve O
    Am J Cardiol; 1986 Feb; 57(7):59D-63D. PubMed ID: 3513516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice-daily administration of oral verapamil in the treatment of essential hypertension.
    Frishman W; Charlap S; Kimmel B; Saltzberg S; Stroh J; Weinberg P; Monuszko E; Wiezner J; Dorsa F; Pollack S
    Arch Intern Med; 1986 Mar; 146(3):561-5. PubMed ID: 3954530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
    Jørgensen NP; Walstad RA
    Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning.
    Smith DH; Neutel JM; Weber MA
    Am J Hypertens; 2001 Jan; 14(1):14-9. PubMed ID: 11206672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of sustained-release verapamil: automatic ambulatory blood pressure monitoring.
    Zachariah PK; Sheps SG; Schriger A
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):133S-142S. PubMed ID: 3540223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and duration of action of sustained-release verapamil in essential hypertension.
    McCormack PM; Latham AN; Mee F; Atkins N; O'Brien ET; O'Malley K
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S34-7. PubMed ID: 2475682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.
    Fuenmayor NT; Faggin BM; Cubeddu LX
    Drugs; 1992; 44 Suppl 1():1-11. PubMed ID: 1283570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of verapamil in patients with hypertension.
    Anderson P; Bondesson U; de Faire U
    Eur J Clin Pharmacol; 1986; 31(2):155-63. PubMed ID: 3803414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive blood pressure monitoring evaluation of verapamil slow-release 240-mg antihypertensive effectiveness.
    Novo S; Alaimo G; Abrignani MG; Longo B; Muratore G; Strano A
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S38-41. PubMed ID: 2475683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of slow-release verapamil on blood pressure and cardiovascular system in essential hypertension.
    Meric M; Adalet K; Erzengin F; Korkut F; Okur O; Büyüköztürk K
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S42-4. PubMed ID: 2475684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study.
    Speders S; Sosna J; Schumacher A; Pfennigsdorf G
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S47-9. PubMed ID: 2475686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.